Company Overview and News


Add EXEL
to your dashboard

Headline News

Exelixis: Primed For Excellence

2017-11-17 seekingalpha
For investors a bit late to the game, it appears now is a good time to initiate a position in Exelixis. (109-0)

How To Make Money With Gilead?

2017-11-16 seekingalpha
Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. (51-0)

Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

2017-11-10 zacks
Endo International plc (ENDP - Free Report) reported third-quarter 2017 results wherein both earnings and revenues surpassed estimates. Earnings from continuing operations were 91 cents which beat the Zacks Consensus Estimate of 70 cents. However, earnings declined 10% from the year-ago quarter. (56-1)

Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up

2017-11-09 zacks
Perrigo Company plc (PRGO - Free Report) reported third-quarter 2017 adjusted earnings of $1.39 per share, which beat the Zacks Consensus Estimate of $1.10 by 26.4%. The bottom line increased 13% from the year-ago figure. (35-0)

VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

2017-11-09 zacks
VIVUS Inc. (VVUS - Free Report) reported a loss of 6 cents per share in the third quarter of 2017, which was narrower than a loss of 9 cents in the year-ago period and the Zacks Consensus Estimate of 13 cents. (169-0)

Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

2017-11-09 zacks
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 5 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 6 cents. However, the figure was in line with the loss recorded in the year-ago quarter. (132-0)

Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

2017-11-09 zacks
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) reported a loss of 40 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $1.88. The company had reported a loss of $2.06 in the year-ago quarter. (90-0)

Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

2017-11-09 zacks
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported third-quarter 2017 earnings of 11 cents per share (including the impact of stock-based compensation) comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents. However, earnings were lower than 20 cents recorded a year ago. (83-0)

Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

2017-11-08 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) reported third-quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye-care drug Eylea. (45-0)

Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

2017-11-08 zacks
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) reported third-quarter 2017 adjusted earnings of $3.22 per share, beating the Zacks Consensus Estimate of $2.89. The bottom line also increased 23% from the year-ago figure. (61-0)

Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

2017-11-08 zacks
Agenus Inc. (AGEN - Free Report) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents. (109-0)

AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

2017-11-08 zacks
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) reported a third-quarter 2017 adjusted loss of 2 cents per share (excluding loss due to change in fair value of warrant liability), narrower than the Zacks Consensus Estimate of 5 cents as well as the year-ago loss of 8 cents. However, including loss related to change in fair value of warrant liability, net loss per share for   the quarter was 22 cents. (348-1)

Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

2017-11-08 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 14 cents per share in third-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of  21 cents. The company had reported a loss of 39 cents in the year-ago quarter. (215-0)

Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

2017-11-08 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) reported a loss of 86 cents per share in the third quarter of 2017, wider than the year-ago loss of 51 cents. The Zacks Consensus Estimate was pegged at a loss of 66 cents. (248-0)

Exelixis, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-06 seekingalpha
The following slide deck was published by Exelixis, Inc. in conjunction with their 2017 Q3 earnings call. (31-0)

CUSIP: 30161Q104